Azilect® In Wearing-Off (AIWO)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Pharma GmbH
• Collaborator: Anfomed GmbH
• Treatments: Rasagiline

Criteria

Inclusion:

• idiopathic Parkinson's disease based on the UK Brain Bank criteria,

• Wearing-off / end-of-dose akinesia

• at least 18 years old,

• written consent to participate in the study.

Exclusion:

• contraindications according to the SmPC of Azilect®,

• treatment with Azilect® in the past 3 months and / or

• suffering from a relevant cognitive impairment and therefore neither understand the patient information, nor can give their consent to participate.